ReviewExperimental dermatology2026
Spatial and Single-Cell Multi-Omics Analyses of T-Cell Subsets and Interactions in Melanoma Lymph Node Metastasis.
Review in Experimental dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Melanoma is a highly immunogenic malignancy, yet responses to systemic therapy remain variable. The tumour-draining lymph node (TDLN), including the sentinel lymph node (SLN) during early regional spread, is not only a site of metastatic dissemination but also an important setting for T-cell priming and immune regulation. Conventional classification of nodes as tumour-positive or tumour-negative provides essential staging information but reveals little about their immune state. Single-cell immune transcriptomics, T-cell receptor sequencing and single-cell epigenomics now allow T-cell states, clonal dynamics and regulatory programmes to be examined in greater detail. Spatial transcriptomics, multiplex imaging, spatial proteomics and emerging spatial metabolomics add the anatomical context needed to determine where these cells and molecular programmes occur within the intact tissue architecture. In this review, we examine how these approaches are being utilised to study T-cell heterogeneity, spatial organisation and immune interactions within melanoma TDLNs, together with the emerging contribution of artificial intelligence (AI)-assisted pathology. We also critically evaluate how these technologies are applied, with attention to tissue requirements, spatial resolution, molecular coverage, computational demands, scalability to archival haematoxylin and eosin (H&E) imaging cohorts and careful interpretation of predicted or inferred spatial features. By combining biological profiling with methodological appraisal, we highlight how multi-omics immune signatures may refine nodal disease assessment and guide future biomarker development, while noting that clinical translation will require standardised analytical pipelines and disease-specific validation across independent melanoma cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.